GloriaBio Approved to Launch PD-1 in China for Hodgkin's Lymphoma
August 31, 2021 at 05:38 AM EDT
Gloria Biosciences was approved to launch its anti-PD-1 mAb to treat recurrent or refractory classical Hodgkin’s lymphoma. The PD-1, zimberelimab, was discovered by CRO WuXi Biotech using Ligand Pharma's OmniRat® program. Gloria has rights to zimberelimab in China . GloriaBio is also testing zimberelimab in solid tumors and has been granted Breakthrough status for cervical cancer patients in China. The company, also known as Guangzhou Yuheng Biological, was established in 2016 by Yuheng Pharma and WuXi Biotech. More details.... Share this with colleagues: // //